Audentes Therapeutics, Inc. (NASDAQ:BOLD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Monday.

According to Zacks, “Audentes Therapeutics, Inc. is a biotechnology company which focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases. The company’s product pipeline consists of AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia and AT982 for the treatment of pompe disease, which are in pre-clinical trial stage. Audentes Therapeutics, Inc. is based in San Francisco, California. “

Other research analysts have also recently issued reports about the company. Bank of America Corporation restated a “buy” rating and set a $33.00 target price (up from $23.00) on shares of Audentes Therapeutics in a report on Friday, September 22nd. ValuEngine cut Audentes Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, August 11th. William Blair assumed coverage on Audentes Therapeutics in a report on Tuesday, October 17th. They set an “outperform” rating and a $35.00 target price on the stock. Evercore ISI assumed coverage on Audentes Therapeutics in a report on Wednesday, August 16th. They set an “outperform” rating and a $23.00 target price on the stock. Finally, Raymond James Financial, Inc. assumed coverage on Audentes Therapeutics in a report on Thursday, October 12th. They set a “market perform” rating on the stock. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $25.71.

Audentes Therapeutics (BOLD) traded up 0.68% during midday trading on Monday, hitting $25.15. The stock had a trading volume of 258,999 shares. Audentes Therapeutics has a 12-month low of $13.13 and a 12-month high of $33.43. The firm has a 50-day moving average of $26.58 and a 200-day moving average of $26.58. The company’s market cap is $698.77 million.

Audentes Therapeutics (NASDAQ:BOLD) last issued its earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($0.10). Equities research analysts forecast that Audentes Therapeutics will post ($3.13) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Zacks Investment Research Upgrades Audentes Therapeutics, Inc. (BOLD) to “Hold”” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another website, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/23/zacks-investment-research-upgrades-audentes-therapeutics-inc-bold-to-hold.html.

In related news, SVP David Nagler sold 3,750 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $25.00, for a total value of $93,750.00. Following the transaction, the senior vice president now directly owns 3,750 shares in the company, valued at $93,750. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Mary Newman sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $20.00, for a total value of $200,000.00. Following the completion of the transaction, the senior vice president now owns 10,000 shares in the company, valued at $200,000. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 766,500 shares of company stock worth $21,443,730. Insiders own 47.30% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ardsley Advisory Partners lifted its holdings in Audentes Therapeutics by 59.7% in the second quarter. Ardsley Advisory Partners now owns 20,072 shares of the biotechnology company’s stock valued at $384,000 after acquiring an additional 7,500 shares during the last quarter. California State Teachers Retirement System lifted its holdings in Audentes Therapeutics by 128.8% in the second quarter. California State Teachers Retirement System now owns 27,000 shares of the biotechnology company’s stock valued at $517,000 after acquiring an additional 15,200 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Audentes Therapeutics by 1,086.0% in the second quarter. The Manufacturers Life Insurance Company now owns 13,580 shares of the biotechnology company’s stock valued at $260,000 after acquiring an additional 12,435 shares during the last quarter. Redmile Group LLC lifted its holdings in Audentes Therapeutics by 77.8% in the second quarter. Redmile Group LLC now owns 1,459,616 shares of the biotechnology company’s stock valued at $27,922,000 after acquiring an additional 638,780 shares during the last quarter. Finally, State Street Corp lifted its holdings in Audentes Therapeutics by 231.6% in the second quarter. State Street Corp now owns 221,276 shares of the biotechnology company’s stock valued at $4,234,000 after acquiring an additional 154,544 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Get a free copy of the Zacks research report on Audentes Therapeutics (BOLD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.